GLP-1 drugs are taking much oxygen out of the biotechnology trade. However, many investors have been eyeing other areas in the sector, particularly cancer research. Novartis AG (NYSE: NVS) is up over ...

At age 60, funny lady Sykes gets serious about her breast cancer journey and discusses life as a wife, mom, and professional.

FRANKFURT (Reuters) -Swiss drugmaker Novartis on Thursday forecast sales growth of 5% to 6% per year to 2030, on a currency-adjusted basis, as higher forecast peak sales for cancer drugs Kisqali and ...

Novartis AG boosted its sales targets for two key cancer drugs, underscoring confidence in its oncology pipeline. The Swiss drugmaker raised its peak sales guidance for breast cancer drug Kisqali to ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. The new approval, which triples Pluvicto’s ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier ...

Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA.

Viz.ai, a company involved in AI-backed imaging and care coordination, is collaborating with pharma giant Novartis to develop proprietary AI-powered workflows inside the Viz Oncology Suite. Viz.ai ...

Novartis said the U.S. Food and Drug Administration has approved the use of Pluvicto against a certain type of prostate cancer. The drug maker said Friday that the FDA green-lit the use of Pluvicto to ...

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s (NYSE:NVS) Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of ...